20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Shares of Alpine Immune Sciences (NASDAQ:ALPN) moved higher in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 13.21% year over year to ($0.46), which missed the estimate of ($0.40).
Revenue of $7,193,000 rose by 945.49% year over year, which beat the estimate of $6,480,000.
Guidance
Alpine Immune Sciences hasn't issued any earnings guidance for the time being.
Alpine Immune Sciences hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 10, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/nkbmxcne
Price Action
52-week high: $16.37
Company's 52-week low was at $6.66
Price action over last quarter: down 22.32%
Company Profile
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!